Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.
about
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo.Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice.From hype to reality: data science enabling personalized medicine
P2860
Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Real-world first-line treatmen ...... US community oncology setting.
@en
type
label
Real-world first-line treatmen ...... US community oncology setting.
@en
prefLabel
Real-world first-line treatmen ...... US community oncology setting.
@en
P2093
P2860
P1433
P1476
Real-world first-line treatmen ...... US community oncology setting.
@en
P2093
Amy P Abernethy
Ashwini Arunachalam
Caroline McKay
David P Carbone
Rachael Sorg
Thomas Burke
Xiting Cao
P2860
P304
P356
10.1371/JOURNAL.PONE.0178420
P407
P577
2017-06-23T00:00:00Z